We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Collaboration Helps Accelerate Launch of New Malaria Test

By LabMedica International staff writers
Posted on 07 Feb 2016
Print article
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).
The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean principles” experts.

The accelerated product transfer and launch of the innovative “illumigene Malaria” test by Meridian Bioscience, Inc. (Cincinnati, OH, USA) was facilitated by collaboration with Lean Continuous Improvements, LLC (LCI; Cincinnati, OH, USA), a consulting firm expert in applying “lean principles” in conjunction with project management, to help minimize wasted time while maximizing product quality, and to facilitate team energy and conflict resolution. Meridian recognized a need to streamline the tasks and activities required to move its new test from product development phase through to final regulatory approval, and ultimately to clinical laboratories.

John A. Kraeutler, Chairman of the Board & CEO, Meridian, said, “The development of diagnostic tests is a highly complex process that involves multiple operating departments within Meridian. For us to achieve the highest efficiency in product transfer without sacrificing quality, we knew that we needed outside assistance. The team at LCI has a deep background in “Lean Transformation,” having worked with many diverse companies in many diverse areas such as Health Care, Lean Accounting, Product Development, Manufacturing, Supply Chain, and Total Maintenance. Our collaboration on the malaria test launch was a true partnership in which Meridian’s product-transfer team worked hand-in-hand with our LCI consultant to achieve a 3-month improvement in the final timeline. By increasing ownership, the team became a more disciplined, cohesive group.”

Gregory Battle, president and CEO of LCI, said, “The Meridian Bioscience C-Suite management team gave us great support all the way through the project. Lean Transformation is a ‘Systems’ approach designed so that clear standards are established and hidden problems surface, are identified, and resolved. With Lean Transformation, solutions are not ‘implemented,’ but rather problems are solved.”

He continued: “We start with grasping the situation where the work is done. We identify a problem area—a key business challenge with opportunities to demonstrate lean as a transformational system. [...] Leadership is the key for success; the top leaders within the facility must be actively, visibly involved in the vision-setting session and implementation.”

Related Links:

Meridian Bioscience
illumigene Malaria


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more